Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by tylerreddickon May 30, 2024 9:03am
78 Views
Post# 36064050

RE:RE:RE:RE:RE:RE:Our ceo problem

RE:RE:RE:RE:RE:RE:Our ceo problem
biorun wrote: Don't mean to insult your business intelligence here, but how much effort in salary dollars do you think went into all the internal due diligence to bring it to the point of signing.

- scientific evaluation 
- market studies
- legal costs 
- safety consultation 
- management time
- internal consultation with their global manager network
- corporate overhead allocated to the project cost center
- accounting/finance team verifications

All of that time added up is well beyond $1M, that is for sure.




Maybe, maybe not, but that is 1 million or so.
You said "millions", with an "s".
I don't mean to insult YOUR business intelligence, but you do spew a lot of nonsense.

When AbbVie announces they are coming out with a product, then and only then can we celebrate.
So far, this looks like yet another Rodan and Fields 'bend over and take it' fiasco.
<< Previous
Bullboard Posts
Next >>